China Immunotech (Beijing) Biotechnology Co., Ltd.
Works in Cardiovascular · Dermatology · Hematology · Immunology · Musculoskeletal · Neurology · Ophthalmology · Renal & urogenital · Women's health
China Immunotech (Beijing) Biotechnology Co., Ltd. is a clinical trial sponsor. It has 6 active clinical trials with 97 planned participants, across 9 therapeutic areas. Since 2021 it has completed 1 trial and stopped 1 early.
Trial track record · since 2021
Pipeline · 6 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about China Immunotech (Beijing) Biotechnology Co., Ltd
China Immunotech (Beijing) Biotechnology Co., Ltd is lead sponsor of 6 active clinical trials on ClinicalTrials.gov, with 97 planned participants, in Cardiovascular, Dermatology, Hematology, Immunology and other areas. Since 2021 it has completed 1 trial and stopped 1 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with China Immunotech (Beijing) Biotechnology Co., Ltd; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-14.
Approve Suite is not affiliated with China Immunotech (Beijing) Biotechnology Co., Ltd..
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.